The Impact of Hypertension on Treatment Outcomes in Benign Prostatic Hyperplasia Patients: A Comprehensive Systematic Review

Around 25% of men over 60 suffer from both hypertension and benign prostatic hyperplasia (BPH), two prevalent age-related illnesses that affect males. Through an analysis of the literature over the past ten years, this study attempts to thoroughly assess the effect of hypertension on the treatment outcomes of patients with BPH. Initially, 500 papers were obtained from internet databases such as Google Scholar, SpringerLink, SagePub, and PubMed. Following three screening stages, eight pertinent papers were chosen for full-text examination. The impact of hypertension on BPH treatment outcomes—including symptom severity, drug response, and surgical outcomes—was evaluated in these articles. The findings indicate that hypertension is associated with poorer treatment outcomes in BPH patients, including reduced efficacy of alpha-blockers and 5-alpha-reductase inhibitors, as well as an increased risk of surgical complications. In clinical practice, the study highlights the necessity of coordinated care approaches that manage both hypertension and BPH. In order to manage these two illnesses concurrently, healthcare providers must take a comprehensive strategy, taking into account possible drug interactions and improving treatment approaches. In order to create specialized treatment plans for this high-risk group, more study is required to examine the underlying mechanisms that connect hypertension to the development of BPH and treatment response. In the end, this would improve the quality of life for men with both illnesses by improving patient outcomes and lowering complication.